Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Photoswitchable nanoparticles for in vivo cancer chemotherapy.

Tong R, Chiang HH, Kohane DS.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19048-53. doi: 10.1073/pnas.1315336110. Epub 2013 Nov 4.

2.

Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin.

Tang N, Du G, Wang N, Liu C, Hang H, Liang W.

J Natl Cancer Inst. 2007 Jul 4;99(13):1004-15. Epub 2007 Jun 27. Erratum in: J Natl Cancer Inst. 2007 Sep 6;99(17):1347.

3.

Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors.

Ding D, Zhu Z, Liu Q, Wang J, Hu Y, Jiang X, Liu B.

Eur J Pharm Biopharm. 2011 Sep;79(1):142-9. doi: 10.1016/j.ejpb.2011.01.008. Epub 2011 Jan 25.

PMID:
21272637
4.

Lipid-based drug delivery systems for cancer treatment.

Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA.

Curr Drug Targets. 2011 Jul 1;12(8):1151-65. Review.

PMID:
21443475
5.
6.

Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation.

Larina IV, Evers BM, Ashitkov TV, Bartels C, Larin KV, Esenaliev RO.

Technol Cancer Res Treat. 2005 Apr;4(2):217-26.

PMID:
15773791
7.

Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.

Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna G, Park W, Chilkoti A, Koning GA, ten Hagen TL, Needham D, Dewhirst MW.

Cancer Res. 2012 Nov 1;72(21):5566-75. doi: 10.1158/0008-5472.CAN-12-1683. Epub 2012 Sep 4.

8.

Nanotechnologies for noninvasive measurement of drug release.

Moore T, Chen H, Morrison R, Wang F, Anker JN, Alexis F.

Mol Pharm. 2014 Jan 6;11(1):24-39. doi: 10.1021/mp400419k. Epub 2013 Nov 26. Review.

9.

Deep penetration of nanoparticulate drug delivery systems into tumors: challenges and solutions.

Li L, Sun J, He Z.

Curr Med Chem. 2013;20(23):2881-91. Review.

PMID:
23651305
10.

Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors.

Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, Zhang J, He S, Liang XJ.

Cancer Res. 2013 Jan 1;73(1):319-30. doi: 10.1158/0008-5472.CAN-12-2071. Epub 2012 Oct 16.

11.

Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.

Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC, Kim DD.

Biomaterials. 2011 Oct;32(29):7181-90. doi: 10.1016/j.biomaterials.2011.06.028. Epub 2011 Jul 5.

PMID:
21733572
12.

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.

Maeda H, Nakamura H, Fang J.

Adv Drug Deliv Rev. 2013 Jan;65(1):71-9. doi: 10.1016/j.addr.2012.10.002. Epub 2012 Oct 23. Review.

PMID:
23088862
13.

Multistage nanoparticle delivery system for deep penetration into tumor tissue.

Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popovic Z, Jain RK, Bawendi MG, Fukumura D.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2426-31. doi: 10.1073/pnas.1018382108. Epub 2011 Jan 18. Erratum in: Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6336.

14.

Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

Ernsting MJ, Murakami M, Roy A, Li SD.

J Control Release. 2013 Dec 28;172(3):782-94. doi: 10.1016/j.jconrel.2013.09.013. Epub 2013 Sep 25. Review.

15.

Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel.

Jiang X, Xin H, Gu J, Xu X, Xia W, Chen S, Xie Y, Chen L, Chen Y, Sha X, Fang X.

Biomaterials. 2013 Feb;34(6):1739-46. doi: 10.1016/j.biomaterials.2012.11.016. Epub 2012 Dec 2.

PMID:
23211449
16.

Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy.

Bisht S, Maitra A.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):415-25. doi: 10.1002/wnan.43. Review.

PMID:
20049807
17.

Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity.

Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, Xiang R, Reisfeld RA.

Nanomedicine. 2011 Dec;7(6):665-73. doi: 10.1016/j.nano.2011.03.001. Epub 2011 Mar 17.

PMID:
21419870
18.

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

Shapira A, Livney YD, Broxterman HJ, Assaraf YG.

Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Review.

PMID:
21330184
19.

PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.

Acharya S, Sahoo SK.

Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83. doi: 10.1016/j.addr.2010.10.008. Epub 2010 Oct 20. Review.

PMID:
20965219
20.

Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.

Feng SS, Mei L, Anitha P, Gan CW, Zhou W.

Biomaterials. 2009 Jul;30(19):3297-306. doi: 10.1016/j.biomaterials.2009.02.045. Epub 2009 Mar 19.

PMID:
19299012
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk